Zhongshan Laibo Ruichen Biomedicine Co. Ltd. has patented new polypeptides and their drug conjugates potentially useful for the treatment of osteoporosis.

Hutchmed Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting EGFR (HER1; erbB1) linked to cytotoxic drug potentially useful for the treatment of cancer and autoimmune diseases.

Amplia Therapeutics Ltd. has discovered new focal adhesion kinase (FAK) inhibitors potentially useful for the treatment of cancer and fibrosis.

Scinnohub Pharmaceutical Co. Ltd. has disclosed new biazacycloalkane compounds acting as menin (MEN1)/KMT2A (MLL) and/or MEN1 (M327I mutant)/KMT2A (MLL) and/or MEN1 (T349M mutant)/KMT2A (MLL) interaction inhibitors potentially useful for the treatment of cancer and diabetes.

Open Source Therapeutics Co. Ltd. has reported new nitrogen-containing heterocyclic compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer.

Merck Sharp & Dohme LLC (MSD) has disclosed new glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and type 2 diabetes.

Alterome Therapeutics Inc. has described new GTPase KRAS inhibitors potentially useful for the treatment of cancer.

Treeline Biosciences Inc. has patented new tetrahydroisoquinoline heterobifunctional proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety potentially useful for the treatment of cancer.

Kallyope Inc. has identified new gastrin-releasing peptide receptor (GRPR) agonists potentially useful for the treatment of gastrointestinal disorders and obesity.

Coultreon Biopharma BV has synthesized new macrocyclic cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers potentially useful for the treatment of cancer.